BR112016013887A2 - Uso de um inibidor do ponto de verificação e de uma micobactéria morta pelo calor não patogênica de variante bruta para terapia de câncer - Google Patents

Uso de um inibidor do ponto de verificação e de uma micobactéria morta pelo calor não patogênica de variante bruta para terapia de câncer

Info

Publication number
BR112016013887A2
BR112016013887A2 BR112016013887A BR112016013887A BR112016013887A2 BR 112016013887 A2 BR112016013887 A2 BR 112016013887A2 BR 112016013887 A BR112016013887 A BR 112016013887A BR 112016013887 A BR112016013887 A BR 112016013887A BR 112016013887 A2 BR112016013887 A2 BR 112016013887A2
Authority
BR
Brazil
Prior art keywords
patogenic
crude
variant
heat
cancer therapy
Prior art date
Application number
BR112016013887A
Other languages
English (en)
Other versions
BR112016013887B1 (pt
Inventor
Akle Charles
Grange John
Bilyard Kevin
Original Assignee
Immodulon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immodulon Therapeutics Ltd filed Critical Immodulon Therapeutics Ltd
Publication of BR112016013887A2 publication Critical patent/BR112016013887A2/pt
Publication of BR112016013887B1 publication Critical patent/BR112016013887B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112016013887-2A 2013-12-20 2014-12-16 Uso de um inibidor do ponto de verificação e de uma micobactéria morta pelo calor não patogênica de variante bruta para terapia de câncer BR112016013887B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1322725.1A GB201322725D0 (en) 2013-12-20 2013-12-20 Cancer therapy
GB1322725.1 2013-12-20
PCT/GB2014/053717 WO2015092382A1 (en) 2013-12-20 2014-12-16 A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy

Publications (2)

Publication Number Publication Date
BR112016013887A2 true BR112016013887A2 (pt) 2017-08-08
BR112016013887B1 BR112016013887B1 (pt) 2023-02-14

Family

ID=50071260

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013887-2A BR112016013887B1 (pt) 2013-12-20 2014-12-16 Uso de um inibidor do ponto de verificação e de uma micobactéria morta pelo calor não patogênica de variante bruta para terapia de câncer

Country Status (18)

Country Link
US (7) US10610577B2 (pt)
EP (1) EP3082956B1 (pt)
JP (2) JP6858558B2 (pt)
KR (1) KR101820393B1 (pt)
CN (2) CN105979964B (pt)
AU (2) AU2014369510B2 (pt)
BR (1) BR112016013887B1 (pt)
CA (1) CA2932659C (pt)
ES (1) ES2913460T3 (pt)
GB (1) GB201322725D0 (pt)
IL (1) IL246083B2 (pt)
MX (1) MX2016007709A (pt)
NZ (1) NZ721009A (pt)
PL (1) PL3082956T3 (pt)
PT (1) PT3082956T (pt)
RU (1) RU2719934C2 (pt)
SG (2) SG11201604602TA (pt)
WO (1) WO2015092382A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA109108C2 (uk) 2008-12-09 2015-07-27 Дженентек, Інк. Антитіло до pd-l1 та його застосування для посилення функції t-клітин
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CA2990107A1 (en) 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
JP6971239B2 (ja) * 2015-10-05 2021-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
WO2017087587A1 (en) * 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. PD1/CTLA4 Binders
JP7000322B2 (ja) 2015-12-16 2022-02-04 メルク・シャープ・アンド・ドーム・コーポレーション 抗ｌａｇ３抗体および抗原結合性フラグメント
CN108367082A (zh) 2016-01-08 2018-08-03 桃太郎源株式会社 使用REIC/Dkk-3基因和检查点抑制剂的组合疗法
EP3195878A1 (en) * 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
GB201601248D0 (en) * 2016-01-22 2016-03-09 Immodulon Therapeutics Ltd Cancer therapy
CN109476751B (zh) 2016-05-27 2024-04-19 艾吉纳斯公司 抗tim-3抗体及其使用方法
AU2017284499A1 (en) * 2016-06-17 2019-01-31 Osaka University Intratumoral vein formation promoter
WO2018107244A1 (en) * 2016-12-15 2018-06-21 Progen Pg500 Series Pty Ltd Composition and uses thereof
US11077179B2 (en) 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome
JP7017011B2 (ja) * 2017-11-06 2022-02-08 ソウル大学校産学協力団 マイコバクテリウムパラゴルドネの抗癌免疫治療法用途
CN112672758A (zh) * 2018-06-25 2021-04-16 英摩杜伦治疗学公司 癌症治疗
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
GB201919428D0 (en) * 2019-12-30 2020-02-12 Immodulon Therapeutics Ltd Immunotherapeutic treatment of cancer
CN113358872B (zh) * 2021-06-03 2022-10-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于评估肿瘤免疫治疗疗效的标志物组及系统
US20240024449A1 (en) * 2022-07-20 2024-01-25 Immunology Diagnostics, LLC Methods and compositions for improving immune system function

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064476A2 (en) 1999-04-23 2000-11-02 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
WO2003049751A1 (en) 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
ATE481985T1 (de) 2002-07-03 2010-10-15 Ono Pharmaceutical Co Immunpotenzierende zusammensetzungen
CN1859851A (zh) * 2002-07-12 2006-11-08 约翰斯霍普金斯大学 间皮素疫苗与模型系统
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
AU2006306521B2 (en) 2005-10-21 2011-12-22 Medical College Of Georgia Research Institute, Inc. The induction of indoleamine 2,3-dioxygenase in dendritic cells by TLR ligands and uses thereof
GB0526033D0 (en) 2005-12-21 2006-02-01 Bioeos Ltd Method
WO2007112316A2 (en) 2006-03-24 2007-10-04 Morton Donald L Mycobacterial immunotherapy for cancer treatment
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
RU2350338C2 (ru) * 2007-05-14 2009-03-27 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ лечения поверхностного рака мочевого пузыря
KR101586617B1 (ko) * 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US8367075B2 (en) * 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
CN103796680A (zh) * 2011-06-21 2014-05-14 约翰霍普金斯大学 用于增强针对赘生物的基于免疫的治疗的聚焦放射
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
CA2848985A1 (en) * 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US8617520B2 (en) * 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
JP6448533B2 (ja) * 2012-05-15 2019-01-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐｄ−１／ｐｄ−ｌ１シグナル伝達を破壊することによる癌免疫療法
WO2014064240A1 (en) * 2012-10-26 2014-05-01 Institut Gustave Roussy Methods for predicting the sensitivity of a subject to immunotherapy
WO2014181221A2 (en) 2013-05-08 2014-11-13 Ashwin Bharadwaj Heat sink
GB201308325D0 (en) 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
KR102395498B1 (ko) 2014-01-06 2022-05-09 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
CA2990107A1 (en) 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy

Also Published As

Publication number Publication date
MX2016007709A (es) 2017-02-23
CA2932659A1 (en) 2015-06-25
AU2020201754B2 (en) 2021-04-01
JP2017500341A (ja) 2017-01-05
US10994002B2 (en) 2021-05-04
CA2932659C (en) 2022-10-18
PL3082956T3 (pl) 2022-05-23
GB201322725D0 (en) 2014-02-05
AU2014369510B2 (en) 2019-12-12
US20170028047A1 (en) 2017-02-02
ES2913460T3 (es) 2022-06-02
US10925952B2 (en) 2021-02-23
JP6858558B2 (ja) 2021-04-14
CN111671908A (zh) 2020-09-18
IL246083B2 (en) 2023-03-01
EP3082956B1 (en) 2022-04-20
PT3082956T (pt) 2022-07-29
BR112016013887B1 (pt) 2023-02-14
US20200215176A1 (en) 2020-07-09
US20210213127A1 (en) 2021-07-15
CN105979964A (zh) 2016-09-28
EP3082956A1 (en) 2016-10-26
SG11201604602TA (en) 2016-07-28
KR20160093023A (ko) 2016-08-05
US11000584B2 (en) 2021-05-11
RU2719934C2 (ru) 2020-04-23
US20210213128A1 (en) 2021-07-15
US20190008942A1 (en) 2019-01-10
WO2015092382A1 (en) 2015-06-25
SG10202111098RA (en) 2021-11-29
US10610577B2 (en) 2020-04-07
AU2020201754A1 (en) 2020-03-26
IL246083A0 (en) 2016-07-31
KR101820393B1 (ko) 2018-01-19
CN105979964B (zh) 2020-07-14
RU2016123370A (ru) 2018-01-25
IL246083B (en) 2022-11-01
JP2019196394A (ja) 2019-11-14
US20200215174A1 (en) 2020-07-09
US10610578B2 (en) 2020-04-07
AU2014369510A1 (en) 2016-06-30
NZ721009A (en) 2022-08-26
US20200215175A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
BR112016013887A2 (pt) Uso de um inibidor do ponto de verificação e de uma micobactéria morta pelo calor não patogênica de variante bruta para terapia de câncer
IL251669A0 (en) Cancer treatment using a tlr9 agonist with checkpoint inhibitors
BR112016010224A2 (pt) combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
DK3290407T3 (da) Bromodomæneinhibitorer
CL2014001720S1 (es) Cartucho para toner
HK1222550A1 (zh) 羥化酶抑制劑的藥物製劑
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
CL2016002336A1 (es) Uso de compuestos heterocíclicos para controlar nematodos
BR112015029267A2 (pt) processos para a preparação de desidroepiandrosterona e seus intermediários
ES2544026B1 (es) Dispositivo para presión positiva continua
CL2015003585A1 (es) Combinaciones para el tratamiento de cáncer que comprende un inhibidor de la quinasa mps-1 y un inhibidor de la mitosis
BR112017015409A2 (pt) composições e métodos para completar poços subterrâneos
BR112016014507A2 (pt) uso de laquinimod para retardar progressão da doença de huntington
BR112016000342A2 (pt) Dispositivo para a substituição de conjuntos de roletes
BR112014018431A2 (pt) método para flotação e uso de pelo menos duas cmcs de diferentes características
ES1148286Y (es) Dispositivo compacto para facilitar el reciclado de capsulas de cafe usadas
ES1078444Y (es) Cubierta corredera para piscinas
BR112015023784A2 (pt) métodos de identificação e uso de compostos nematicidas
BR112017028601A2 (pt) uso de compostos de cloroquina e clemizol para tratamento de condições inflamatórias e cancerosas
CO6940396A2 (es) Discriminación de fluidos para uso con un pozo subterráneo
FI20175714A (fi) Aktivoidut puolijohdeyhdisteet joilla on korotettu sähkökemiallinen reaktiivisuus sekä näihin liittyvät menetelmät
ES1079026Y (es) Candelabro para tanatorio o similar
ES1078710Y (es) Estructura hinchable para puesto ambulante
ES1129380Y (es) Pasarela para playas
ES1083355Y (es) Mecanismo para cortinas enrollables

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2014, OBSERVADAS AS CONDICOES LEGAIS